Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran

Dabigatran (DAB) is an orally administered thrombin inhibitor. Both DAB and its main metabolite dabigatran acylglucuronide (DABG) have established anticoagulant effects. Here, we aimed to compare the relative anticoagulant effects of DABG and DAB in humans. Anticoagulant effects of DAB and DABG were...

Full description

Bibliographic Details
Main Authors: Jong-Min Kim, Jihyeon Noh, Jin-Woo Park, Hyewon Chung, Kyoung-Ah Kim, Seung Bin Park, Jun-Seok Lee, Ji-Young Park
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Pharmaceutics
Subjects:
dabigatran
dabigatran acylglucuronide
thrombin generation
anticoagulation
Online Access:https://www.mdpi.com/1999-4923/14/2/257

Internet

https://www.mdpi.com/1999-4923/14/2/257

Similar Items